ClinicalTrials.gg

Program

NTX-2001

A development code.

Its studies are mostly in Alcoholism, led by Newleos Therapeutics.

Furthest: phase 1, since Apr 3, 20261 company-led study, 1 open or runningNext primary completion: Mar 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Newleos Therapeutics11 open or runningphase 1since Apr 3, 2026Apr 3, 2026Mar 2027phase 1 · NCT07520292

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 3, 2026First study: phase 1 study in AlcoholismFirst studyNCT07520292 · 50 planned · United States

Ahead

  1. Mar 2027Primary completion: phase 1 study in AlcoholismNCT07520292

TargetBeta

TAAR1 →read by rule
“The Effects of NTX-2001, a Novel TAAR1 Partial Agonist, on Alcohol Consumption in Adults With Alcohol Use Disorder: A Phase 1b, Randomized, Placebo-Controlled, Proof-of-Concept Study”study text, by rule · the study

Other programs on TAAR1

ProgramCompanyFurthest phaseStudies
ulotarontruleOtsukaphase 330

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07520292Alcoholism · United States1RecruitingMar 202750

How it is read

Names in the registry

  • “NTX-2001”, 1 entry

Codes read as this program: NTX2001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.